New hope for ITP patients: daratumumab takes on rituximab in head-to-head trial

NCT ID NCT07297563

First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 18 times

Summary

This study compares two antibody drugs, daratumumab and rituximab, in 160 adults with immune thrombocytopenia (ITP) whose condition did not improve or came back after steroid treatment. The main goal is to see which drug better raises platelet counts to safe levels by week 12 without needing rescue therapy. Participants are randomly assigned to one of the two treatments in an open-label design.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chinese Academy of Medical Science and Blood Disease Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.